Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension, delineated by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. PAH affects around 1,000 people every year in the United States.
Know more about the PAH, its symptoms, and causes through the newsletter. The newsletter overlays a brief introduction of the disease, its causes, and symptoms.
It also proffers key highlights of the PAH epidemiological scenario in the 7MM, and trends doe the study period 2017-30, along with the market landscape, marketed therapies, key companies investing in the space, and pipeline therapies.
The Pulmonary Arterial Hypertension Newsletter focuses on significant activities on the research front, major clinical trials ongoing, and their outcomes, as well as the support the patients are getting from the international organizations.
Through the Pulmonary Arterial Hypertension Newsletter series, DelveInsight aims to shed light on the debilitating and disabling diseases that lower down the quality of lives of people. Subscribe to our newsletter series for more such information into Life Science vertical.
Know More About What’s Covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Pipeline drugs
- Key Companies
- R&D in the field
- Top conferences
- Support from International organizations
Source:– https://www.delveinsight.com/whitepaper-newsletter/pulmonary-arterial-hypertension-pah-newsletter
#healthcare #digitalhealth #healthtech #medtech #clinicaltrials #medicaldevices #research #biotech #data #health #opportunities #pharmaceuticalindustry #diagnostics #cancer #medicine #work
DelveInsight 